 |
answer text |
<p>The Department invests £1.3 billion per year into health research, with more spent
on cancer than any other disease group, through the National Institute for Health
and Care Research (NIHR). We work closely with UK Research and Innovation (UKRI) and
the Medical Research Council (MRC), who are responsible for channelling a large proportion
of the Department for Science, Innovation and Technology’s investments in this area.
Our officials meet regularly to discuss a wide range of our investments, including
into lobular and other breast cancers, to drive the maximum collective research impact
on policy, practice, and individual lives. While research to understand the mechanisms
of cancer, including lobular breast cancer, is largely funded through UKRI and the
MRC, the NIHR invests in translational and implementation research to drive innovations
into policy and practice.</p><p> </p><p>Launched in 2023, the Lobular Moonshot Project
is a high-level funding proposal and campaign to raise money to support the Institute
for Cancer Research (ICR), with whom we meet regularly, to invest in fellowships and
projects in lobular breast cancer. We are proud to have invested £29 million in the
ICR and Royal Marsden NIHR Biological Research Centre in 2022, supporting their efforts
to strengthen research into cancer, again including lobular breast cancer. This is
complemented by wider investments into breast cancer research, for example, a £1.3
million project to determine whether an abbreviated form of breast magnetic resonance
imaging can detect breast cancers missed by screening through mammography, such as
lobular breast cancer. Our support to the NIHR Clinical Research Network has enabled
the delivery of 10 further lobular breast-cancer related studies.</p><p> </p><p>Additionally,
the NIHR supports breast cancer research funded by research partners in the charity
and public sectors through the NIHR’s Clinical Research Network (CRN). Over the last
five years, the CRN has supported delivery of 10 lobular breast cancer-related studies
conducted by other partners. While the NIHR cannot respond to direct solicitations
for funding, instead commissioning on the basis of research excellence, we would welcome
more applications from researchers on lobular breast cancer, including from the ICR.
The NIHR funds research on cancer prevention, detection, diagnosis, treatment, and
care, which saves lives.</p>
|
|
